PerkinElmer, Inc. (PKI) Given Consensus Recommendation of “Hold” by Analysts

Shares of PerkinElmer, Inc. (NYSE:PKI) have received a consensus rating of “Hold” from the sixteen research firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $67.17.

A number of equities analysts have recently commented on the company. Jefferies Group LLC restated a “hold” rating and issued a $69.00 price objective (up from $58.00) on shares of PerkinElmer in a report on Tuesday, June 20th. Cantor Fitzgerald restated a “hold” rating on shares of PerkinElmer in a report on Sunday, July 16th. BidaskClub downgraded PerkinElmer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 14th. Piper Jaffray Companies reiterated a “buy” rating and set a $81.00 target price on shares of PerkinElmer in a report on Friday, August 4th. Finally, Cowen and Company reiterated a “market perform” rating and set a $70.00 target price (up from $61.00) on shares of PerkinElmer in a report on Tuesday, June 20th.

TRADEMARK VIOLATION NOTICE: “PerkinElmer, Inc. (PKI) Given Consensus Recommendation of “Hold” by Analysts” was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.themarketsdaily.com/2017/09/13/perkinelmer-inc-pki-given-consensus-recommendation-of-hold-by-analysts.html.

In other PerkinElmer news, insider Andrew Okun sold 4,358 shares of the firm’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $65.00, for a total transaction of $283,270.00. Following the completion of the sale, the insider now owns 16,799 shares in the company, valued at approximately $1,091,935. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.20% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Credit Suisse AG grew its position in shares of PerkinElmer by 6.5% in the 1st quarter. Credit Suisse AG now owns 108,618 shares of the medical research company’s stock worth $6,306,000 after acquiring an additional 6,665 shares in the last quarter. Swiss National Bank grew its position in shares of PerkinElmer by 0.8% in the 1st quarter. Swiss National Bank now owns 181,200 shares of the medical research company’s stock worth $10,520,000 after acquiring an additional 1,400 shares in the last quarter. Morgan Stanley grew its position in shares of PerkinElmer by 10.5% in the 1st quarter. Morgan Stanley now owns 272,720 shares of the medical research company’s stock worth $15,834,000 after acquiring an additional 25,976 shares in the last quarter. Boston Private Wealth LLC grew its position in shares of PerkinElmer by 10.0% in the 1st quarter. Boston Private Wealth LLC now owns 10,736 shares of the medical research company’s stock worth $623,000 after acquiring an additional 975 shares in the last quarter. Finally, Prudential Financial Inc. grew its position in shares of PerkinElmer by 0.6% in the 1st quarter. Prudential Financial Inc. now owns 151,573 shares of the medical research company’s stock worth $8,801,000 after acquiring an additional 900 shares in the last quarter. Hedge funds and other institutional investors own 91.69% of the company’s stock.

PerkinElmer (NYSE PKI) opened at 68.56 on Wednesday. PerkinElmer has a 52-week low of $45.35 and a 52-week high of $70.16. The firm has a market capitalization of $7.56 billion, a P/E ratio of 20.68 and a beta of 0.74. The firm has a 50-day moving average price of $65.73 and a 200 day moving average price of $62.60.

PerkinElmer (NYSE:PKI) last released its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. The company had revenue of $547.00 million for the quarter, compared to the consensus estimate of $554.14 million. PerkinElmer had a return on equity of 13.44% and a net margin of 16.80%. The company’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same period last year, the business posted $0.67 EPS. Analysts forecast that PerkinElmer will post $2.89 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 10th. Shareholders of record on Friday, October 20th will be paid a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, October 19th. This represents a $0.28 dividend on an annualized basis and a yield of 0.41%. PerkinElmer’s dividend payout ratio (DPR) is presently 8.46%.

PerkinElmer Company Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Analyst Recommendations for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply